Patents by Inventor Carl T. Wild

Carl T. Wild has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8318425
    Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: November 27, 2012
    Assignees: The United States of America, as represented by the Secretary, Department & Human Services, Myrexis, Inc.
    Inventors: Karl Salzwedel, Feng Li, Carl T. Wild, Graham P. Allaway, Eric O. Freed
  • Publication number: 20110142847
    Abstract: The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against “entry relevant” gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry.
    Type: Application
    Filed: October 30, 2007
    Publication date: June 16, 2011
    Applicants: Panacos Pharmaceuticals, Inc., GOVERNMENT OF THE U.S., REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Carl T. Wild, Carol D. Weiss
  • Publication number: 20100291680
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Application
    Filed: June 2, 2010
    Publication date: November 18, 2010
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild, Shawn O'Lin Barney, Dennis Michael Lambert, Stephen Robert Petteway, JR., Alphonse J. Langlois
  • Publication number: 20100221264
    Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme.
    Type: Application
    Filed: July 6, 2009
    Publication date: September 2, 2010
    Applicants: Panacos Pharmaceuticals, Inc., The Govt. of the U.S.A. as represented by the Secretary, Dept. of Health & Human Services
    Inventors: Karl Salzwedel, Feng Li, Carl T. Wild, Graham P. Allaway, Eric O. Freed
  • Patent number: 7537765
    Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: May 26, 2009
    Assignees: Panacos Pharmaceuticals, Inc., The United States of America as represented by the Department of Health and Human Services
    Inventors: Karl Salzwedel, Feng Li, Carl T. Wild, Graham P. Allaway, Eric O. Freed
  • Publication number: 20080233559
    Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme.
    Type: Application
    Filed: December 21, 2007
    Publication date: September 25, 2008
    Inventors: Karl SALZWEDEL, Feng Li, Carl T. Wild, Graham P. Allaway, Eric O. Freed
  • Publication number: 20080200550
    Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme.
    Type: Application
    Filed: May 24, 2005
    Publication date: August 21, 2008
    Applicants: V.I. TECHNOLOGIES, INC., THE GOV. OF US AS REP. BY THE SEC. DEP. OF HEALTH
    Inventors: Karl Salzwedel, Feng Li, Carl T. Wild, Graham P. Allaway, Eric O. Freed
  • Patent number: 7365221
    Abstract: Betulin and dihydrobetulin acyl derivatives according to the present invention have been found to have potent anti-HIV activity. The compounds of the present invention have Formula I as described herein, or pharmaceutically acceptable salts thereof; wherein R1 is a C2-C20 substituted or unsubstituted carboxyacyl or ester thereof; R2 is hydrogen, halogen, hydroxyl or —OR3, R3 is C2-C20 substituted or unsubstituted carboxyacyl; and R4 is hydrogen or C(C6H5)3; wherein the dashed line represents an optional double bond between C20 and C29.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: April 29, 2008
    Assignees: Panacos Pharmaceuticals, Inc., The University of North Carolina at Chapel Hill, Niigata University of Pharmacy and Applied Life Sciences
    Inventors: Graham P. Allaway, Carl T. Wild, Yoshiki Kashiwada, Kuo-Hsiung Lee
  • Patent number: 7311916
    Abstract: The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against “entry relevant” gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: December 25, 2007
    Assignees: The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, Panacos Pharmaceuticals, Inc.
    Inventors: Carl T. Wild, Carol D. Weiss
  • Patent number: 7273614
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Grant
    Filed: October 9, 2002
    Date of Patent: September 25, 2007
    Assignee: Duke University
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild
  • Patent number: 7122190
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Grant
    Filed: October 9, 2002
    Date of Patent: October 17, 2006
    Assignee: Duke University
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild, Shawn O'Lin Barney, Dennis Michael Lambert, Stephen Robert Petteway, Alphonse J. Langlois
  • Publication number: 20040265320
    Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme.
    Type: Application
    Filed: January 29, 2004
    Publication date: December 30, 2004
    Inventors: Karl Salzwedel, Feng Li, Carl T. Wild, Graham P. Allaway, Eric O. Freed
  • Patent number: 6824783
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 30, 2004
    Assignee: Duke University
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild
  • Publication number: 20040213801
    Abstract: The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against “entry relevant” gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry.
    Type: Application
    Filed: September 10, 2003
    Publication date: October 28, 2004
    Applicant: Panacos Pharmaceuticals, Inc.
    Inventors: Carl T. Wild, Carol D. Weiss
  • Patent number: 6768007
    Abstract: 3′,4′-di-O-camphanoyl-(+)-cis-khellactone analogs according to the present invention have been found to have anti-HIV activity. The compounds of the present invention have the following formula: or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein R1, R2, R3, R4, X, and Z are set in the specification. The invention is also directed to pharmaceuticals compositions comprising one or more compounds of Formula I, optionally further comprising one or more anti-viral agents or immunostimulating agents. Further, the invention is directed to the use of compounds of Formula I for the inhibition of a retroviral infection in cells or tissue of an animal, for the treatment of a patient suffering from a retroviral-related pathology, for the prevention of transmission of HIV infection from an HIV infected pregnant woman to a fetus, and for the prevention of transmission of HIV infection during sexual intercourse.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: July 27, 2004
    Assignees: Panacos Pharmaceuticals, Inc., The University of North Carolina at Chapel Hill
    Inventors: Kuo-Hsiung Lee, Lan Xie, Graham P. Allaway, Carl T. Wild
  • Publication number: 20040132011
    Abstract: The invention is directed to methods for identifying compounds that decrease the ability of a virus, such as HIV-1, to infect previously uninfected cells by inducing conformational changes in viral envelope proteins, and the compounds discovered by such methods.
    Type: Application
    Filed: October 16, 2003
    Publication date: July 8, 2004
    Applicant: Panacos Pharmaceuticals, Inc.
    Inventors: Graham P. Allaway, Carl T. Wild, Karl Salzwedel
  • Publication number: 20040131629
    Abstract: Betulin and dihydrobetulin acyl derivatives according to the present invention have been found to have potent anti-HIV activity. The compounds of the present invention have Formula I as described herein, or pharmaceutically acceptable salts thereof, wherein R1 is a C2-C20 substituted or unsubstituted carboxyacyl, R2 is hydrogen, chloro, bromo, or hydroxy, R4 is hydrogen or C(C6H5)3; wherein the dashed line represents an optional double bond between C20 and C29.
    Type: Application
    Filed: September 26, 2003
    Publication date: July 8, 2004
    Applicants: Panacos Pharmaceuticals, Inc., The University of North Carolina at Chapel Hill, Niigata University of Pharmacy and Applied Science
    Inventors: Graham P. Allaway, Carl T. Wild, Yoshiki Kashiwada, Kuo-Hsiung Lee
  • Publication number: 20040052820
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Application
    Filed: October 8, 2002
    Publication date: March 18, 2004
    Applicants: Duke University, Trimeris, Inc.
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild, Shawn O?apos;Lin Barney, Dennis Michael Lambert, Stephen Robert Petteway, Alphonse J. Langlois
  • Publication number: 20040033235
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Application
    Filed: January 6, 2003
    Publication date: February 19, 2004
    Applicant: Duke University
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild
  • Publication number: 20030181382
    Abstract: This invention relates to human immunodeficiency virus (HIV) protein fragments which have antiviral activity, and particularly relates to HIV peptides derived from the HIV transmembrane glycoprotein (gp41) which inhibit HIV-induced cell-cell fusion. This invention further relates to methods for the inhibition of enveloped viral infection, and to methods that modulate biochemical processes which involve coiled coil peptide interactions.
    Type: Application
    Filed: April 15, 2003
    Publication date: September 25, 2003
    Applicant: Duke University
    Inventors: Carl T. Wild, Thomas J. Matthews, Dani P. Bolognesi